Assay Detail
Binding
CHEMBL5734995
Review assay metadata, readout intent, target linkage, and publication context from the same page.
Inhibition Assay: LANCE method of PerkinElmer Inc. was used in the assay, and recombinant CDK4/CyclinD3 (Item No.: 04-105) and CDK6/CyclinD3 (Item No.: 04-107) kinases were purchased from Cama Biosciences, Inc. Substrate ULight-MBP (Item No.: TRF0109) and Eu-labeled anti-MBP antibody (Item No.: TRF0201) were purchased from PerkinElmer. HEPES PH7.5 (Item No.: #15630080), DTT (Item No.: # D1532), MgCl2 (Item No.: # AM9530G), EGTA (Item No.: # E1219), and EDTA (Item No.: # AM9260G) were purchased from Life Technology. Firstly, a 1× buffer solution A (50 mM HEPES, PH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Tween 20 and 2 mM DTT) was prepared. A compound to be tested was dissolved in DMSO to 1 mM, serially diluted with DMSO, and then diluted 25-fold with the buffer solution A (final concentration of DMSO: 1%). CDK4/CyclinD3 and CDK6/CyclinD3 were diluted respectively with the buffer solution A. Finally, the buffer solution A was used to prepare the substrate and ATP. 4 μl of CDK4/CyclinD3 (final concentration: 2 nM) or CDK6/CyclinD3 (final concentration: 4 nM), 2 μl of the diluted compound, and 4 μl of a mixture of the substrate (final concentration: 50 nM) and ATP (final concentration: 200 μM) were added to reaction wells, and the resulting mixture was kept at room temperature to react for 1 h. Then, an EDTA solution was added to terminate the reaction, and Eu-labeled anti-MBP antibody was added and the resulting mixture was incubated at room temperature for additional 1 h. EnVision was used to read fluorescent signals (excitation wavelength: 320 nM, emission wavelength: 615 nM and 650 nM).
21
Total Activities
7
Compounds Tested
3
Activity Types
0
Assay Parameters
Assay Information
| Assay Type | Binding |
| Organism | Homo sapiens |
| Confidence | 9 — Direct single protein target |
| Curated By | Autocuration |
Publication
Substituted pyrrolopyrimidine CDK inhibitor, pharmaceutical composition containing same and use thereof
Activity Statistics
| Type | Count | Avg pChEMBL | Best pChEMBL |
|---|---|---|---|
| IC50 | 7 | 7.81 | 8.24 |
| kon | 7 | - | - |
| k_off | 7 | - | - |
Compounds Tested
| Compound | Name | Phase | Activities | Best pChEMBL |
|---|---|---|---|---|
| CHEMBL6008170 | — | — | 3 | 8.24 |
| CHEMBL5922296 | — | — | 3 | 8.01 |
| CHEMBL5761239 | — | — | 3 | 7.96 |
| CHEMBL5788017 | — | — | 3 | 7.73 |
| CHEMBL5956743 | — | — | 3 | 7.68 |
| CHEMBL3545110 | RIBOCICLIB | 4.0 | 3 | 7.57 |
| CHEMBL5826084 | — | — | 3 | 7.51 |
Activity Data
| Compound | Name | Type | Rel. | Value | Units | pChEMBL |
|---|---|---|---|---|---|---|
| CHEMBL6008170 | — | IC50 | = | 5.7 | nM | 8.24 |
| CHEMBL5922296 | — | IC50 | = | 9.85 | nM | 8.01 |
| CHEMBL5761239 | — | IC50 | = | 11.1 | nM | 7.96 |
| CHEMBL5788017 | — | IC50 | = | 18.7 | nM | 7.73 |
| CHEMBL5956743 | — | IC50 | = | 21.0 | nM | 7.68 |
| CHEMBL3545110 | RIBOCICLIB | IC50 | = | 26.9 | nM | 7.57 |
| CHEMBL5826084 | — | IC50 | = | 30.6 | nM | 7.51 |
| CHEMBL3545110 | RIBOCICLIB | kon | = | - | — | - |
| CHEMBL3545110 | RIBOCICLIB | k_off | = | - | s-1 | - |
| CHEMBL6008170 | — | kon | = | - | — | - |
| CHEMBL6008170 | — | k_off | = | - | s-1 | - |
| CHEMBL5956743 | — | kon | = | - | — | - |
| CHEMBL5956743 | — | k_off | = | - | s-1 | - |
| CHEMBL5788017 | — | k_off | = | - | s-1 | - |
| CHEMBL5761239 | — | kon | = | - | — | - |
| CHEMBL5761239 | — | k_off | = | - | s-1 | - |
| CHEMBL5922296 | — | kon | = | - | — | - |
| CHEMBL5922296 | — | k_off | = | - | s-1 | - |
| CHEMBL5826084 | — | kon | = | - | — | - |
| CHEMBL5826084 | — | k_off | = | - | s-1 | - |
| CHEMBL5788017 | — | kon | = | - | — | - |